Initial Dose Escalation News Today

Analysis to be Presented Showed Peanut Allergy Treatment with PALFORZIA was Associated with Improvements in Health-Related Quality of Life among Patients and Caregivers -Additional Data to be Presented

/PRNewswire/ -- Ryvu Therapeutics (WSE: RVU) a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...

/PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...

/PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address...

Posted on 192 Aimmune Therapeutics, a Nestlé Health Science company developing and commercializing treatments for potentially life-threatening food allergies, today announced new clinical data from a pooled analysis of three controlled phase 3 (PALISADE 1, RAMSES, ARTEMIS 3, ARC008, ARC011) trials of PALFORZIA ® [Peanut ( Arachis hypogaea) Allergen Powder-dnfp]. These data will be presented at the American Academy of Allergy, Asthm...

This story was originally published on Jan. 31, 2020. As part of MedPage Today s review of the past years top stories, we are republishing it, along with an update on peanut allergy therapies and related developments as the year went on. WASHINGTON -- Aimmune Therapeutics oral immunotherapy for peanut allergy gained FDA approval late Friday, for treating individuals age 4-17, the agency said. To be sold as Palforzia, the product consists of purified peanut proteins, to be administered in care...